Rapport Therapeutics, Inc.

Biotechnology • Healthcare • Boston, MA, United States • RAPP (NGM)

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.

857 321 8020 1325 Boylston Street, Boston, MA 02215, United States

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 7.2% - Here's What Happened - MarketBeat

MarketBeat • Jan 2

Rapport Therapeutics stock holds Buy rating at Goldman Sachs on epilepsy drug efficacy - Investing.com

Investing.com • Dec 19

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? - The Motley Fool

The Motley Fool • Dec 22

Rapport Therapeutics (RAPP) Valuation Check After a 60% Year-to-Date Share Price Surge - Yahoo Finance

Yahoo Finance • Dec 7

Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire

GlobeNewswire • Dec 18

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Rapport Therapeutics, Inc. had layoffs?

No layoff events have been recorded for Rapport Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Rapport Therapeutics, Inc. have?

Rapport Therapeutics, Inc. has approximately 69 employees.

What industry is Rapport Therapeutics, Inc. in?

Rapport Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Rapport Therapeutics, Inc. a publicly traded company?

Yes, Rapport Therapeutics, Inc. is publicly traded under the ticker symbol RAPP on the NGM. The company has a market capitalization of approximately $1.44 billion.

Where is Rapport Therapeutics, Inc. headquartered?

Rapport Therapeutics, Inc. is headquartered in Boston, MA, United States at 1325 Boylston Street, Boston, MA 02215, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.